Pulmonx
Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.
Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.
Pulmonx has raised $66.0M across 1 round. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Pulmonx is featured in
Similar companies
Intellihealth creates medical technology software that aids in diagnosing diseases associated with obesity. One of the company's primary offerings, Evolve, allows healthcare professionals to provide effective obesity treatment to patients, whether through telehealth or in-person consultations.
Ember Copilot is a Software Development firm offering a tool to reduces medical claim denials.
Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology care delivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home. It was founded in 2020 and is based in Nashville, Tennessee.
QSimulate is currently hiring for various positions such as scientists, software engineers, project managers, and business development, as the team expands. Our office locations include Boston MA, Berkeley CA, and Ghent, Belgium. Remote options are also considered for technical roles. For further details, please contact us at info@qsimulate.com.
100 Healthy Years • Your new routine of 120+ advanced lab tests explained by the world's top doctors
Perelel is a supplement manufacturer designed for various stages of a woman's reproductive life cycle.
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
DifferentKind is a software solution designed for dental professionals to focus on patient needs, allowing them to enhance patient results and satisfaction. This ultimately leads to increased trust, loyalty, and revenue for dental practices. The software utilizes AI technology for clinical consultations and executive decision-making.
NextSense opens mind wellbeing with genuine information experiences and useful, logical insight for everyday living. It plans to catalyze cerebrum wellbeing in science and culture. The organization was established in 2020 and is settled in Mountain View, California.
MR3Health is a unique new organization that brings an inventive mix of administration and demonstrated innovation to patients and guarantors to save lives impacted by diabetic neuropathy and lower the expenses of medical services. MR3Health is extraordinarily situated for progress with various assets obscure to most new businesses. These incorporate existing licenses, a FDA cleared clinical gadget upheld by clinical preliminaries, and a supervisory crew with an abundance of business, assembling, and clinical experience. It was sent off in 2015 and is settled in San Antonio, Texas.
MiSalud offers a unique combination of personalized preventative wellness services, along with traditional healthcare via Spanish speaking physicians.
Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.